25 Oct 2026
2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC
Author: admintech | Filed under: Press ReleaseSAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PRNewswire/ — Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune,…